Maximum Daily Dose of Extended‑Release Dextroamphetamine‑Amphetamine

FDA‑Approved Maximum Dose

The FDA and the Physicians’ Desk Reference designate 40 mg per day as the absolute maximum total dose for extended‑release dextroamphetamine‑amphetamine in both children and adults, regardless of formulation (immediate‑release or extended‑release). 1

The American Academy of Child and Adolescent Psychiatry (AACAP) guidelines commonly cap routine clinical dosing at 40 mg per day for amphetamine‑type stimulants. 1
In rare adult cases, dosing up to 0.9 mg/kg (approximately 40 mg for a typical adult) has been reported without exceeding the 40 mg ceiling. 3
Exceptional circumstances may justify up to 40 mg of amphetamines (or 65 mg of methylphenidate) when lower doses are ineffective and higher doses are documented to cause no adverse effects. 3

For children weighing less than 25 kg, a single dose should not exceed 10 mg of the extended‑release formulation. 1
The overall 40 mg daily ceiling also applies to pediatric patients, but younger or smaller children often cannot tolerate doses approaching this limit. 3

Clinicians must record that target symptoms remained uncontrolled at lower doses before escalating to the 40 mg limit. 3
Documentation must confirm that higher doses are not producing adverse effects such as weight loss, elevated blood pressure, or agitation. 3
Ongoing monitoring for tolerance development should be noted in the medical record. 3

If the 40 mg maximum fails to achieve adequate symptom control, further dose escalation is not recommended. 1
Instead, clinicians should switch to an alternative stimulant class (e.g., methylphenidate if amphetamine was first tried). 3
Add or intensify psychosocial and behavioral interventions to augment pharmacotherapy. 1
Re‑evaluate the diagnosis and assess for comorbid conditions that may explain treatment resistance. 1

Approximately 70 % of patients respond to either amphetamine or methylphenidate alone, and ≈90 % respond when both stimulant classes are trialed sequentially; therefore, switching medication class is more effective than exceeding the maximum dose of a single agent. 3

Blood pressure and pulse should be measured quarterly in adults and annually in children receiving stimulant therapy. 1
Weight, height, appetite, sleep quality, and cardiovascular parameters require closer surveillance as doses approach the 40 mg ceiling. 1
Standardized rating scales completed by parents, teachers, or the patient should be used to determine whether higher dosing yields meaningful clinical benefit. 3